Drugs / Evofosfamide
Evofosfamide
Trials 27 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01746979 Comparator | Dec 2012 → Feb 2016 | pancreatic adenocarcinoma | ImmunoGenesis | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | evofosfamide | “A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in...” PMID 27535748 ↗ Aug 20165“Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.” PMID 34190375 ↗ Jul 2021 |
| Known as | EVO | “Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.” PMID 34190375 ↗ Jul 2021 |
| Known as | Evofosfamida | ChEMBL registry synonym — accepted as the source's own label CHEMBL260046 ↗ |
| Known as | HAP-302 | ChEMBL registry synonym — accepted as the source's own label CHEMBL260046 ↗ |
| Known as | TH-302 | “The goal of this study is to provide continuation therapy with TH-302 to patients with soft tissue sarcomas who obtained response or stabilization of disease with prior...” NCT02712567 ↗24“The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).” NCT01721941 ↗ |
| Known as | TH-302 (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophos-phate | “TH-302 (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophos-phate is a nitroimidazole-linked prodrug of a brominated version of isophosphoramide...” NCT02433639 ↗ |
| Modality | Other / unclassified | “TH-302 is an investigational hypoxia-activated prodrug” PMID 25512461 ↗ Dec 2014 |
| Route | Intravenous | “TH-302 will be administered by IV infusion over 30-60 minutes” NCT00742963 ↗ |